הכנסה תפעולית לפני ניכוי פחת: Cardio Diagnostics (CDIO)

Cardio Diagnostics is developing an AI platform for the early detection of heart pathologies, leveraging the implementation of Epi+Gen CHD tests. Monitoring of EBITDA_Co captures the operational efficiency of the business, with this metric equal to 0.00. The uniqueness of epigenetic methods allows the company to exercise pricing power, while streamlined express transport channels for biosamples guarantee the stability of telemedicine services.

This metric reflects the daily cash flow from core operations before depreciation and interest, allowing for the exclusion of accounting adjustments to assess the business's actual liquidity. For Cardio Diagnostics (CDIO), the stability of this value would confirm the effectiveness of the transition to a subscription-based IT services model and integration with insurance companies, which clearly demonstrates the EBITDA as of the current date.